title: Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia.
abstract: BACKGROUND
  Adipocyte-fatty acid binding protein (A-FABP) is a circulating protein expressed in adipocytes and macrophages. Several recent studies demonstrated that A-FABP might be involved in the pathogenesis of metabolic syndrome, particularly in dyslipidaemia, insulin resistance and atherosclerosis. The aim of this study was to investigate the influence of atorvastatin treatment (20 mg day(-1) for 3 months) on serum A-FABP value in subjects with hyperlipidaemia.
  
  
  METHODS
  Anthropometric and serum analyses were performed for body mass index, A-FABP, triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST), high sensitive C-reactive protein (hs-CRP), creatine kinase (CK) and glucose on 26 subjects (BMI 30.3 +/- 6.0, mean age 62 +/- 10 years) with hyperlipidaemia who met the criteria: total cholesterol > 5.2 mmol L(-1), LDL cholesterol > 3.3 mmol L(-1) and triglycerides < 3 mmol L(-1).
  
  
  RESULTS
  After the 3-month therapy, a significant reduction in total cholesterol (P < 0.001), LDL cholesterol (P < 0.001), glucose (P < 0.001), A-FABP (from 44.6 +/- 26.2 to 38.6 +/- 19.3 g L(-1), P < 0.01), uric acid (P < 0.05), AST (P < 0.05) and triglycerides (P < 0.05) values was observed. No difference was found in BMI, CK, ALT, hs-CRP, or HDL cholesterol values. A significant difference in the serum A-FABP value before and after the therapy remains after the correction for total cholesterol value (P < 0.001). A positive correlation between serum A-FABP and glucose was found (P < 0.05).
  
  
  CONCLUSIONS
  In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions.
authors.affiliation: University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic. michal.karpisek@email.cz
authors.forename: M
authors.initials: M
authors.lastname: Karpisek
authors.forename: D
authors.initials: D
authors.lastname: Stejskal
authors.forename: H
authors.initials: H
authors.lastname: Kotolova
authors.forename: P
authors.initials: P
authors.lastname: Kollar
authors.forename: G
authors.initials: G
authors.lastname: Janoutova
authors.forename: R
authors.initials: R
authors.lastname: Ochmanova
authors.forename: L
authors.initials: L
authors.lastname: Cizek
authors.forename: D
authors.initials: D
authors.lastname: Horakova
authors.forename: R Ben
authors.initials: RB
authors.lastname: Yahia
authors.forename: R
authors.initials: R
authors.lastname: Lichnovska
authors.forename: V
authors.initials: V
authors.lastname: Janout
mesh_terms: D017667:Adipocytes / Q000187:drug effects*; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D050556:Fatty Acid-Binding Proteins / Q000187:drug effects*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy; D008875:Middle Aged; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D050556:Fatty Acid-Binding Proteins; D006538:Heptanoic Acids; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin